SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review.

摘要: Objectives We aimed to review SARS-CoV-2 seroprevalence studies conducted in Europe understand how they may be used inform ongoing control strategies for COVID-19. Design Scoping of peer-reviewed publications and manuscripts on preprint servers from January 2020 15 September 2020. Primary measure Seroprevalence estimate (and lower upper CIs). For across a country or territory, we the CIs compared them total number reported infections calculate ratio expected infections. Results identified 23 population-based Europe. Among 12 general population studies, ranged 0.42% among residual clinical samples Greece 13.6% an area high transmission Gangelt, Germany. Of eight blood donors, 0.91% North-Western Germany 23.3% high-transmission Lombardy region, Italy. In three which recruited individuals through employment, 0.5% factory workers Frankfurt, Germany, 10.2% university employees Milan, comparison nationally cases, extent infection, as derived these estimates, is manyfold higher largely heterogeneous. Conclusion Exposure virus has not reached level infection that would prevent further circulation virus. Effective vaccine candidates are urgently required deliver immunity population.